Are you Dr. Wang?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 33 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
2201 Inwood Rd
Dallas, TX 75390Phone+1 214-645-4673Fax+1 214-645-2615
Summary
- Dr. Jue Wang, MD is an oncologist in Dallas, Texas. He is currently licensed to practice medicine in Texas, Arizona, and Nebraska. He is affiliated with University of Texas Southwestern Medical Center and is an Assistant Professor at University of Nebraska Medical Center College of Medicine.
Education & Training
University of Texas Medical Branch HospitalsFellowship, Medical Oncology, 2005 - 2007- University of Texas Medical Branch HospitalsResidency, Internal Medicine, 2002 - 2005
Suzhou Medical CollegeClass of 1990
Certifications & Licensure
AZ State Medical License 2014 - 2025
TX State Medical License 2023 - 2025
NE State Medical License 2007 - 2014- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013
- Fellow (FACP) American College of Physicians, 2011
Clinical Trials
- Zoledronate in Preventing Skeletal (Bone)-Related Events in Men Who Are Receiving Androgen Deprivation Therapy For Prostate Cancer and Bone Metastases Start of enrollment: 2004 Jan 01
- Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer Start of enrollment: 2009 Jul 15
- Lenalidomide and Cyclophosphamide in Treating Patients With Previously Treated Hormone-Refractory Prostate Cancer Start of enrollment: 2010 Mar 04
- Join now to see all
Publications & Presentations
PubMed
- 50 citationsA phase II basket trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART) SWOG S1609: High-grade neuroendocrine neoplasm cohort.Sandip Pravin Patel, Edward Mayerson, Young Kwang Chae, Jonathan R. Strosberg, Jue Wang
Cancer. 2021-09-01 - 76 citationsCharacterization of metastatic urothelial carcinoma via comprehensive genomic profiling of circulating tumor DNANeeraj Agarwal, Sumanta K. Pal, Andrew W. Hahn, Roberto Nussenzveig, Gregory R. Pond
Cancer. 2018-05-15 - 29 citationsCirculating Tumor DNA Alterations in Advanced Urothelial Carcinoma and Association with Clinical Outcomes: A Pilot StudyPetros Grivas, Aly-Khan A. Lalani, Gregory R. Pond, Rebecca J. Nagy, Bishoy Faltas
European Urology Oncology. 2020-10-01
Press Mentions
Comparison of Clinicopathological Characteristics and Response to Neoadjuvant Systemic Therapy in Patients with HER2-Low-Positive and HER2-Zero Breast CancerJanuary 19th, 2023
NMPA Approves IND Application for CT103A, a Fully-Human BCMA CAR-T for the Treatment of Relapsed/Refractory Multiple Myeloma Co-Developed by IASO BIO and Innovent BiologicsOctober 2nd, 2019- Clinical Results of Fully Human BCMA CAR-T for the Treatment of Relapsed/Refractory Multiple Myeloma Co-Developed by IASO BIO and Innovent Presented at the 2019 ASCO and EHA Annual MeetingsJune 19th, 2019
- Join now to see all
Professional Memberships
- Member
- Fellow
